|4Mar 14, 7:30 PM ET

Eiger BioPharmaceuticals, Inc. 4

4 · Eiger BioPharmaceuticals, Inc. · Filed Mar 14, 2017

Insider Transaction Report

Form 4
Period: 2017-03-09
Cory David A
DirectorPresident and CEO
Transactions
  • Award

    Stock Option (Right to Buy)

    2017-03-09+133,000133,000 total
    Exercise: $11.75Exp: 2027-03-09Common Stock (133,000 underlying)
Footnotes (1)
  • [F1]The option vests in equal monthly installments over 48 months measured from March 9, 2017 subject to Reporting Person's continuous service status as of each such date.

Documents

2 files
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION

  • EX-24.4_711996

    POA DOCUMENT